Effects of semaglutide on mortality, cardiovascular, and kidney outcomes across the cardio-kidney-metabolic continuum: a systematic review and meta-analysis
Authors' conclusion
Treatment with semaglutide, compared to placebo, is associated with significant lower incidence of all-cause and CV mortality, as well major CV and kidney events across the continuum of cardio-kidney-metabolic syndrome.
Study context
- Population
- Diverse patient populations across the cardio-kidney-metabolic continuum in randomized controlled trials (RCTs)
- Participants
- 39,204 participants8 trials
- Comparison
- Semaglutide vs placebo
- Outcome
- All-cause and cardiovascular (CV) mortality
Methodological detailsrandom-effects model
- Random-effects model
Pooled result
As reported in the abstract
Semaglutide vs PlaceboHazard ratio (95% CI)P value
All-cause mortality
0.84(0.77–0.92)
P = 0.0001CV mortality
0.83(0.72–0.95)
P = 0.0078Further pooled results
| Outcome | HR (95% CI) | P value | |
|---|---|---|---|
| MACE | 0.82 (0.77–0.87) | P < 0.0001 | |
| Nonfatal MI | 0.75 (0.68–0.84) | P < 0.0001 | |
| Worsening HF | 0.84 (0.73–0.98) | P = 0.0245 | |
| Kidney outcomes | 0.83 (0.73–0.95) | P = 0.0080 | |
| 0.512Hazard ratio (log scale) |
Nonfatal stroke
- No significant effects were observed for nonfatal stroke
Original publication
Effects of semaglutide on mortality, cardiovascular, and kidney outcomes across the cardio-kidney-metabolic continuum: a systematic review and meta-analysis. Cardiovasc Diabetol. Published 25 May 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →